North Immunology secures $180 million and a Nasdaq listing via a reverse merger with Aethlon Medical to advance its dual-pathway inflammatory drug, NOR-101, into clinical trials.
North Immunology gains public listing via reverse merger and secures $180 million private placement to fund operations into 2028, supporting its NOR-101 program.
Existing Aethlon shareholders will be diluted to 4.75% of the combined entity through the reverse merger, leaving them with a small stake and only a contingent value right for the legacy business.
Kymera is mentioned as one of several companies racing to improve on Dupixent, and the entry of North Immunology adds to the competitive landscape without direct immediate impact.
NOR-101 targets the same IL-13 pathway as Sanofi's blockbuster Dupixent, potentially posing a future competitive threat to Dupixent's $17.8 billion sales.
NOR-101, a potential competitor to Dupixent (co-marketed with Sanofi), could eventually pressure Regeneron's revenue from the inflammatory disease drug.
North Immunology aims to overcome limitations of existing therapies like AbbVie's Rinvoq, which could present competitive challenges in the atopic dermatitis market.
North Immunology will list on the Nasdaq under ticker NRTX following a reverse merger with Aethlon Medical, expected to close in Q1 2027. The deal includes a $180 million private placement to fund the development of its lead asset, NOR-101, through 2028. The drug aims to challenge the dominance of Sanofi and Regeneron's Dupixent by targeting both IL-13 and IL-18 inflammatory pathways.
Existing Aethlon shareholders will retain a 4.75% stake in the new entity and receive a contingent value right related to the proceeds from the legacy Hemopurifier business.
NOR-101 is designed to treat atopic dermatitis by targeting both IL-13 and IL-18 pathways, aiming to provide a superior therapeutic profile compared to existing treatments like Dupixent.